Key Xarelto Patents and Expiry Dates
Xarelto (rivaroxaban), made by Bayer and Janssen, has multiple patents covering the drug's composition, formulations, and uses. The primary composition-of-matter patent (US Patent 7,157,456) expired on September 20, 2024, after pediatric exclusivity extensions.[1][2]
When Do Other Patents Expire?
Several method-of-use and formulation patents extend protection:
- US Patent 9,326,945 (oral suspension formulation) expires December 23, 2030.[2]
- US Patent 7,592,339 (twice-daily dosing method) expires May 30, 2026.[2]
- US Patent 9,724,312 (coated tablet formulation) expires March 25, 2034.[2]
These later expiries block generics until resolved through litigation.
Why Multiple Expiry Dates Matter for Generics
Generic entry depends on the "patent thicket." The 2024 expiry opened the door, but ongoing lawsuits (e.g., against Mylan and Sandoz) over remaining patents delay full competition until at least 2026, with some protection possibly to 2034.[1][3] FDA Orange Book lists 15+ Xarelto patents, many challenged via Paragraph IV certifications.[2]
Who Makes Xarelto and Generic Challengers
Bayer HealthCare and Janssen Pharmaceuticals market Xarelto in the US. Generic filers like Mylan (Viatris), Sandoz, and Apotex have ANDAs approved but face injunctions.[2][3]
Impact on Pricing and Availability
Post-2024 expiry, limited generic competition has kept prices high (~$500/month branded). Broader entry after 2026 could drop costs 80-90%.[1]
[1] DrugPatentWatch.com - Xarelto Patents
[2] FDA Orange Book - Rivaroxaban Patents
[3] FDA Paragraph IV Patent Challenge Database